Search

Highlights of Past EHA (HOPE) Asia 2019

The 1st edition of the Highlights of Past EHA (HOPE) Asia 2019 took place in Kolkata, India. The meeting was organized in partnership with regional and national societies in Asia.

Chairs and Members

ChairProf Raúl Córdoba (2020–2025 term)

Co-chairProf Valentín Goede

SWG Steering Committee
Sonja Zweegman (The Netherlands)—interest in multiple myeloma
Tamas Fulop (Canada)—interest in geriatrics and immunology
Giuseppe Rossi (Italy)—interest in indolent lymphomas
Dominique Bron (Belgium)—interest in lymphoma, CLL, and cognitive impairment
Sergio Storti (Italy)—interest in aggressive lymphomas
Lionel Ades…

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Jun 11 2016 Posted in Press releases

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

PRESS RELEASE: The future of research in hematology is here

Jan 27 2016 Posted in Press releases, Advocacy news

“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Jun 10 2016 Posted in Press releases

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Highlights of Past EHA (HOPE) Cairo 2018

EHA returned to Cairo with the 3rd edition of the Highlights of Past EHA (HOPE). The meeting was organized in partnership with regional and national societies in the Middle East and North Africa.

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Jun 10 2016 Posted in Press releases

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

SWG Educational Activities

EHA-SWG SCIENTIFIC MEETING ON INTEGRATED CELL TRACKING IN ONCOHEMATOLOGY: DIAGNOSIS, TARGETED THERAPY AND RESIDUAL DISEASE

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:

MC Béné, Nantes University

G Zini, Università Cattolica S.